Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase TRIM69 (TRIM69) is a member of the tripartite motif (TRIM) family of proteins, characterized by a conserved RING domain, one or two B-box motifs, and a coiled-coil domain structure. TRIM69 functions as both an antiviral effector, particularly in myeloid cells, and a regulator of microtubule stability. It is an interferon-stimulated gene that restricts a broad spectrum of viruses—including HIV-1, HIV-2, SIV, vesicular stomatitis virus, and SARS-CoV-2—by promoting the accumulation of stable microtubules within cells, thereby limiting early phases of viral replication and spread. While TRIM69 possesses E3 ubiquitin ligase activity and can self-ubiquitinate, recent evidence suggests that its antiviral function primarily depends on microtubule stabilization, with the direct cellular substrates and the necessity of E3 ligase activity for this role remaining under investigation. TRIM69 is not currently associated with available drugs, nor is it a known therapeutic biomarker, but as part of the broader TRIM protein family, it is of emerging interest for innate immunity and broad-spectrum antiviral research.
For antiviral action: Promotes the accumulation of stable microtubules, which restricts viral spread in cells—distinct from classical E3 ubiquitin ligase substrate ubiquitination. Mechanism may involve unique cytoskeletal remodeling independent of canonical ubiquitination activity for some functions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase TRIM69 (TRIM69).